Advances in Proteomics & Metabolomics 2024

Dr. Hagen Gegner is an interdisciplinary scientist with expertise in metabolomics, mass spectrometry, and science communication. He earned his Ph.D. from King Abdullah University of Science and Technology (KAUST), where his research focused on understanding the impact of environmental factors on coral reef ecosystems using metabolomics approaches. He then completed a postdoctoral fellowship at the University of Heidelberg, further developing his expertise in targeted metabolomics method development and application in clinical research. Hagen has a proven track record in method development, workflow optimization, and automation using liquid chromatography (LC) coupled to mass spectrometers (MS). He has worked in both academic and corporate settings, leading data generation, analysis, and reporting for clinical as well as toxicology studies. His expertise lies in targeted metabolomics method development and the implementation of quality assurance strategies. He has a deep understanding of the challenges associated with metabolomics sample preparation and study design, particularly in clinical settings. Hagen's recent publications highlight his commitment to advancing the field of metabolomics:

Dr. Christoph Borchers is recognized as a pioneer and leading figure in the development of mass spectrometry-based methods for protein quantification using Multiple Reaction Monitoring (MRM). He has also published more than 300 peer-reviewed papers in scientific journals which have been cited more than 29,000 times (H-factor 82), and is the founder and director of the McGill-Lady Davis Institute Integrated Proteomics Program at the Jewish General Hospital, McGill University, where he is currently a full professor in the Gerald Bronfman Department of Oncology. His research is centred around the improvement, development, and application of proteomics and metabolomics technologies, with a major focus on quantitative targeted proteomics for clinical diagnostics, as well as new mass-spectrometry-based techniques for structural proteomics. Dr. Borchers received his BS, MSc, and PhD degrees from the University of Konstanz, Germany in 1996. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC, he became the director of the Duke–UNC Proteomics Facility and held a faculty position at the UNC Medical School in Chapel Hill, NC (2001-2006). From 2006 to 2019, he was a Professor in the Department of Biochemistry and Microbiology, and Director of the University-Genome British Columbia Proteomics Centre at the University of Victoria, British Columbia, Canada, where he held the Rix BC Leadership Chair in Biomedical and Environmental Proteomics. Dr. Borchers is also involved in promoting proteomics research and education through his involvement with HUPO (International Council Member), the British Columbia Proteomics Network (Executive Committee Member, past Scientific Director) and the Canadian National Proteomics Network (Member, past VP External and Chair of the Board of Directors). He is also a Fellow of the Canadian Academy of Health Sciences.

Fabian Coscia obtained his PhD at the Max Planck Institute of Biochemistry in Martinsried, Germany, under supervision of Prof Matthias Mann. In his doctoral and later postdoctoral work as Marie Curie fellow at the Novo Nordisk Center for Protein Research (University of Copenhagen), he developed and applied single-cell and spatial tissue proteomics workflows, and pioneered a new discovery proteomics concept termed Deep Visual Proteomics. In June 2021, he joined the Max Delbrück Center for Molecular Medicine in Berlin where he is heading the independent research group Spatial Proteomics. His team conducts translational proteomics studies and works at the interface between high-content imaging, deep learning and ultrasensitive mass spectrometry. More recently, he has been awarded an ERC starting grant to study cellular neighborhoods and their impact on the disease related proteome and cancer therapy resistance.

Matteo is a Senior Biomarker Scientist in Owlstone Medical’s Clinical and Translational Science program. With 12+ years’ experience in rare diseases, metabolic disorders, and immunology, his expertise spans academic research and bio/med-tech and management consulting. He is an accomplished project leader, excelling in team-oriented environments for pre- and clinical biomarker discovery.